In what has to be the unkindest cut of all, those expected to benefit from the proposed misuse of march-in rights so the government can impose drug price controls say they don’t support it either. The proponents promoting this hot house theory have seen it denounced by those who created the Bayh-Dole Act as being unauthorized under their law and seen evidence they can’t refute that it would have little impact on drug prices but would devastate small business entrepreneurs in all fields of federally supported research and development. And now they’ve lost the generic drug industry.
Recent Posts
- Life Sciences Masters Panelists Say USPTO’s Controversial Anti-Pharma Rules are Unlikely to Progress
- What Intellectual Property Policy Should Look Like in the Age of AI
- True Respect for Textualism Requires Patent Eligibility Reform
- Copyright Office Denies Proposed AI Security Research Exemption in Triennial Rulemaking Under DMCA
- Other Barks & Bites for Friday, October 25: Microsoft CEO Asks for Changes in Copyright Law; Report Finds 22% Growth in Semiconductor Patent Filings; and Former OpenAI Employee Claims Company Breaks Copyright Law